SNY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 6.54% compared to Sanofi SA's net margin of 21.81%. Sanofi SA's return on equity of 7.55% beat BioNTech SE's return on equity of -3.39%.

Sanofi SA has a consensus price target of $63.84, signalling upside risk potential of 23.96%. On the other hand BioNTech SE has an analysts' consensus of $139.19 which suggests that it could grow by 44.21%. Given that BioNTech SE has higher upside potential than Sanofi SA, analysts believe BioNTech SE is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.578, which suggesting that the stock is 42.246% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.943%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.65%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than BioNTech SE quarterly revenues of $1.3B. Sanofi SA's net income of $531.9M is higher than BioNTech SE's net income of $276.6M. Notably, Sanofi SA's price-to-earnings ratio is 20.61x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 7.80x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 6.54% compared to Sanofi SA's net margin of -117.16%. Sanofi SA's return on equity of 7.55% beat Moderna's return on equity of -29.09%.

Sanofi SA has a consensus price target of $63.84, signalling upside risk potential of 23.96%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 98.66%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.578, which suggesting that the stock is 42.246% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.65%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Moderna quarterly revenues of $956M. Sanofi SA's net income of $531.9M is higher than Moderna's net income of -$1.1B. Notably, Sanofi SA's price-to-earnings ratio is 20.61x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 6.54% compared to Sanofi SA's net margin of -91.76%. Sanofi SA's return on equity of 7.55% beat Novavax's return on equity of --.

Sanofi SA has a consensus price target of $63.84, signalling upside risk potential of 23.96%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 180.35%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.578, which suggesting that the stock is 42.246% less volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.65%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Novavax quarterly revenues of $88.3M. Sanofi SA's net income of $531.9M is higher than Novavax's net income of -$81M. Notably, Sanofi SA's price-to-earnings ratio is 20.61x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 1.34x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.54% compared to Sanofi SA's net margin of 24.22%. Sanofi SA's return on equity of 7.55% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Sanofi SA has a consensus price target of $63.84, signalling upside risk potential of 23.96%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $899.34 which suggests that it could grow by 62.28%. Given that Regeneron Pharmaceuticals has higher upside potential than Sanofi SA, analysts believe Regeneron Pharmaceuticals is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.578, which suggesting that the stock is 42.246% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.65%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Sanofi SA's net income of $531.9M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Sanofi SA's price-to-earnings ratio is 20.61x while Regeneron Pharmaceuticals's PE ratio is 14.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 4.49x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.